Sobi Reports Robust Performance in Q2 2025 Financials
Sobi Delivers Strong Financial Results for Q2 2025
Swedish Orphan Biovitrum AB (publ) (Sobi) has shared its financial report for the second quarter of 2025, revealing remarkable growth across its portfolio and pipeline. This performance highlights Sobi's commitment to improving the lives of patients with rare diseases.
Key Financial Highlights
In the second quarter of 2025, Sobi witnessed an impressive total revenue increase of 13 percent, reflecting a notable 22 percent rise at constant exchange rates. The revenue totaled SEK 6,175 million, compared to SEK 5,442 million in the previous period.
Haematology Revenue Performance
Sobi's haematology sector reported a significant 27 percent growth at constant exchange rates, achieving SEK 4,570 million. This surge was largely fueled by the successful launch of Altuvoct, which alone generated SEK 627 million in revenue. Additionally, the sales of Doptelet reached SEK 1,220 million, while Aspaveli/Empaveli contributed SEK 304 million. However, this growth was slightly tempered by a decline in Vonjo sales, which were SEK 302 million.
Immunology Revenue Growth
In the immunology segment, there was an 11 percent revenue increase at constant exchange rates, totaling SEK 1,288 million. This growth was driven by robust sales of Gamifant and Kineret, with figures reaching SEK 632 million and SEK 749 million respectively.
Strategic Portfolio Performance
The revenue from Sobi's strategic portfolio, which includes key medicines such as Altuvoct and Doptelet, rose dramatically by 65 percent at constant exchange rates, amounting to SEK 3,384 million, compared to SEK 2,224 million in the same period last year.
Profitability Metrics
Sobi reported an adjusted EBITA margin of 34 percent, a rise from 28 percent. This figure excludes items affecting comparability, which amounted to SEK -237 million due to restructuring costs primarily associated with organizational changes in the U.S. and R&D functions. The EBITA itself was SEK 1,863 million, reflecting a margin of 30 percent up from 27 percent in the previous year. Overall EBIT reached SEK 1,010 million, a significant increase from SEK 612 million.
Earnings Per Share
For shareholders, earnings per share (EPS) before dilution stood at SEK 1.85 compared to SEK 0.66 last year, while diluted EPS was SEK 1.83 against SEK 0.65 last year. Furthermore, adjusted EPS before dilution was SEK 2.38, a notable rise from SEK 0.72.
Cash Flow and Future Outlook
Cash flow from operating activities was reported at SEK 1,448 million, down from SEK 2,329 million in the prior year. Looking ahead, Sobi anticipates continued growth with revenue expected to rise by a high single-digit percentage at constant exchange rates. Additionally, the adjusted EBITA margin is projected to remain in the mid-30 percentages.
Conference Call Details
Sobi invites investors, analysts, and media representatives to join a conference call to discuss the Q2 results, scheduled for later today at 14:00 CEST. Participants can expect a detailed presentation followed by a Q&A session, offering an interactive platform to engage with the company’s performance.
About Sobi
Sobi is a dedicated global biopharma company focused on unlocking the potential of breakthrough innovations while transforming the lives of individuals living with rare diseases. With a presence across various regions and a workforce of approximately 1,900 employees worldwide, Sobi is committed to advancing healthcare solutions. In 2024, the company reported an impressive revenue of SEK 26 billion.
Frequently Asked Questions
What is Sobi's main focus as a biopharma company?
Sobi focuses on developing innovative treatments aimed at improving the lives of patients suffering from rare diseases.
How much did Sobi's revenue increase in Q2 2025?
Sobi reported a total revenue increase of 13 percent in Q2 2025 compared to the same quarter in the previous year.
What were the haematology revenue figures for Sobi?
In Q2 2025, Sobi's haematology revenue was SEK 4,570 million, showing a significant growth driven by new product launches.
What is the outlook for Sobi in 2025?
Sobi expects revenue growth in 2025 to be in the high single-digit percentage range at constant exchange rates, along with stable earnings margins.
Where is Sobi headquartered?
Sobi is based in Stockholm and operates globally to address the needs of patients with rare diseases.
About The Author
Contact Thomas Cooper privately here. Or send an email with ATTN: Thomas Cooper as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.